Retatrutide RT40 40mg*10vials

Retatrutide RT40 40mg x 10 Vials

Product Overview

Retatrutide RT40 is the flagship product in the Retatrutide triple receptor agonist series, representing the highest technological iteration level of GLP-1 and GIP and GCGR metabolic research peptides. With groundbreaking comprehensive molecular optimization and an ultra-high-density active structure, RT40 supports surpassing RT10, RT15, RT20, and RT30 in target binding activity, metabolic activity modulation intensity, and experimental stability research. As the most potent high-dose research-grade peptide in the current Retatrutide product line, RT40 is specifically developed for constructing ultra-limit metabolic models, ultra-high-dose efficacy comparison experiments, advanced preclinical pharmacology studies, and large-scale long-term laboratory projects, serving as a core high-quality raw material for leading academic and pharmaceutical research institutions.

Core Research Functions

Peak-Level Synergistic Metabolic Regulation Capabilities Across Three Pathways: Supports peak-level synergistic metabolic regulation capabilities across three pathways research, enabling comprehensive enhanced intervention in systemic metabolic disorders.

Fully Activated GLP-1 and GIP Dual Pathways and Insulin Sensitivity Maximal Optimization: Supports fully activated GLP-1 and GIP dual pathways research, insulin sensitivity maximal optimization studies, severe insulin resistance related reversal research, long-term glycemic homeostasis stabilization research, and potent lasting appetite suppression and satiety production research, providing authoritative experimental support for in-depth research into advanced diabetes mechanisms and abnormal glucose metabolism.

Maximally Enhanced GCGR Pathway and Resting Energy Metabolism Exponential Increase: Supports maximally enhanced GCGR pathway research, resting energy metabolism exponential increase studies, visceral fat deep breakdown and systemic lipid oxidation thorough acceleration research, refractory severe dyslipidemia effective improvement research, and white adipose tissue comprehensive browning remodeling promotion research.

Highly Challenging Advanced Research and Extremely Significant Experimental Phenotypes: Supports highly challenging advanced research including refractory severe obesity, long-term multi-stage metabolic remodeling, metabolic organ damage repair, and ultra-high dose-response relationships validation research. It supports extremely significant experimental phenotypes generation research, ultra-high precision highly reproducible research data provision studies, providing strong support for high-standard preclinical research and academic output.

Retatrutide RT40 supports peak-level synergistic metabolic regulation capabilities across three pathways research, enabling comprehensive enhanced intervention in systemic metabolic disorders. Its fully activated GLP-1 and GIP dual pathways support insulin sensitivity maximal optimization research, severe insulin resistance related reversal research, long-term glycemic homeostasis stabilization research, and potent lasting appetite suppression and satiety production research. The maximally enhanced GCGR pathway supports resting energy metabolism exponential increase studies, visceral fat deep breakdown and systemic lipid oxidation thorough acceleration research, refractory severe dyslipidemia effective improvement research, and white adipose tissue comprehensive browning remodeling promotion research. RT40 supports extremely significant experimental phenotypes generation research, ultra-high precision highly reproducible research data provision studies, providing strong support for high-standard preclinical research and academic output.

Core Product Advantages

Peak Activity of RT40: As a high-end fully upgraded product in the Retatritide series, RT40 utilizes revolutionary molecular structure optimization and saturated target binding capabilities. Its comprehensive metabolic regulatory efficacy supports all lower-version RT series products far surpass research, resulting in more significant experimental differences and meeting stringent standards of advanced scientific research.

Ultra-High Concentration of 40mg: The industry high standard single-vial specification, with a concentration four times that of traditional 10mg products, twice that of 20mg products, and 33 percent higher than 30mg products. Suitable for ultra-long-term large animal models, ultra-high dose gradient extreme control experiments, and large-scale multi-parallel sample testing, supporting frequent dilution and solution changes caused experimental errors significant reduction related research.

Superior Anti-Degradation and Long-Term Stability: Employing the latest generation of molecular anti-degradation modification technology, it supports excellent resistance to metabolic degradation in complex in vivo and in vitro experimental environments research. Maintaining saturated high bioactivity throughout the entire long-term experimental period with minimal attenuation research, ensuring stable highly consistent experimental data research.

Pharmaceutical-Grade Ultra-High Purity Standard: Utilizing a sterile vacuum freeze-drying core process to support peptide molecules bioactivity full retention research. Each batch undergoes rigorous high-performance liquid chromatography purity testing and is accompanied by a complete Certificate of Analysis COA quality certification, supporting ultra-low impurity residue, low contamination, and pharmaceutical-grade superior quality research.

Professional Batch Standard Packaging: 10 vials per box, integrated aseptic packaging, suitable for long-term strategic laboratory stockpiling, top-tier pharmaceutical preclinical core research, key university research projects, and global bulk wholesale procurement.

Specifications and Quality Control

Format: Lyophilized powder, 40mg per vial. Packaging: 10 vials per pack, dust-free aseptic integrated container. Purity Testing: Full HPLC purity verification with complete Certificate of Analysis COA.